Abcellera Biologics vs Cytokinetics
Cytokinetics is the larger business, with $88.0m of revenue in fiscal 2025 against $75.1m for Abcellera Biologics (1.2 times as much). Cytokinetics grew faster (376.6% against 160.6%). Abcellera Biologics kept more of each dollar of sales as profit: a net margin of -194.9% against -891.6%.
| Latest fiscal year | Abcellera BiologicsABCL, 2025 | CytokineticsCYTK, 2025 |
|---|---|---|
| Revenue | $75.1m | $88.0m |
| Revenue growth | 160.6% | 376.6% |
| Net income | −$146m | −$785m |
| Operating margin | -289.0% | -695.4% |
| Net margin | -194.9% | -891.6% |
| Return on equity | -14.5% | — |
| Free cash flow | −$174m | −$535m |
| Cash | $129m | $123m |
| Total debt | $0 | $999m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 562 | 673 |
| Market value | $3.71bn | $7.69bn |
| Price vs our value range | — | — |
| Moat score | 17 (Weak) | 9 (Weak) |
| Insider trades, 12 months | 9 buys, 0 sales | 0 buys, 85 sales |